Health · 1 views
Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk asso…
AI Summary
The investigational monoclonal antibody pacibekitug, which targets interleukin‑6, was shown to maintain lowered levels of inflammation‑related biomarkers for six months. The effect was observed in patients who have chronic kidney disease and heightened inflammatory risk linked to heart disease.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Peroxisome structure can help protect insulin and maintain beta cell healthContinue reading
- Reducing antibiotic courses by two weeks could be possible in patients with infective endocarditisContinue reading
- We tried 15 lotions over three weeks. Here’s which our testers loved – and which left them high and dryContinue reading
- Preclinical study points to cancer drugs as possible treatments for chronic nerve painContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow